EUCTR2007-003808-35-GB进行中（未招募）不适用
Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and glimepiride and sitagliptin.
Servier Research and Development Ltd.0 个研究点目标入组 160 人开始时间: 2007年9月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Men and women aged between 35 and 65 years,
- •- BMI between 24 and 38 Kg/m2 inclusive,
- •- Type 2 diabetic patients diagnosed for more than 3 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Type 1 diabetes, or diabetes subtype other than type 2, eg slow type 1 diabetes, LADA, haemochromatosis or chronic pancreatitis,
- •- History of any major symptomatic hyperglycaemic events,
- •- Metabolic state at risk of rapidly requiring insulin therapy,
- •- Concomitant disease or planned major surgery that could significantly affect glycemic control during the study.
研究者
相似试验
进行中（未招募）
不适用
Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and glimepiride and sitagliptin.MedDRA version: 9.1Level: PTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentType 2 DiabetesEUCTR2007-003808-35-DEInstitut de Recherches Internationales160
进行中（未招募）
1 期
Phase I/II study to evaluate safety and activity of oral administration of S 49076 in combination with gefitinib in adult patients with EGFR mutated advanced non-small cell lung cancer who have progressed while on treatment with EGFR tyrosine kinase inhibitor (TKI) therapy.EUCTR2015-002646-31-ESaboratorios Servier S. L.171
进行中（未招募）
1 期
Phase I/II study to evaluate safety and activity of oral administration of S 49076 in combination with gefitinib in adult patients with EGFR mutated advanced non-small cell lung cancer who have progressed while on treatment with EGFR tyrosine kinase inhibitor (TKI) therapy.ocally advanced or metastatic non-small-cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-002646-31-HUInstitut de Recherche International Servier171
进行中（未招募）
1 期
Phase I/II study to evaluate safety and activity of oral administration of S 49076 in combination with gefitinib in adult patients with EGFR mutated advanced non-small cell lung cancer who have progressed while on treatment with EGFR tyrosine kinase inhibitor (TKI) therapy.ocally advanced or metastatic non-small-cell lung cancerMedDRA version: 20.0 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIB System Organ Class: 100000015840MedDRA version: 20.0 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 100000015841EUCTR2015-002646-31-DEInstitut de Recherche International Servier14
进行中（未招募）
1 期
Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac function and NT-proBNP in patients with chronic heart failure and left ventricular dysfunction not treated with a beta-blocker. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study - S44121 vs placebo in chronic heart failure patients not on betablockerChronic heart failure and left ventricular dysfunctionMedDRA version: 14.1 Level: PT Classification code 10049694 Term: Left ventricular dysfunction System Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2009-011559-38-GBInstitut de Recherches Internationales Servier125